Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws

Apr 21 2003

• By The Pink Sheet

Related Content

FDA NDA/BLA Early Input Letters: How Much Should Be Publicly Disclosed?

Oct 14 2002

PDUFA III “Good Review Management Principles” To Stress Early Action

Mar 18 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window